603456:SSEZhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A Analysis

Zhejiang Jiuzhou Pharmaceutical is trading at CNY 16.89, well below its 20‑day (≈17.31), 50‑day (≈18.16) and 200‑day (≈17.87) moving averages, indicating short‑term pressure. The RSI sits at ~39, suggesting the stock is approaching oversold territory, while the MACD remains bearish with a tiny negative histogram. Technical momentum is neutral, but the price is near the identified support level of CNY 16.20 and volume is trending upward, hinting at a possible bounce.
Fundamentally, the company shows a solid revenue growth of 7.4% and healthy margins (gross ~33%, operating ~27%). The forward PE of ~13.8 is well below the industry average of ~26.5, and the DCF‑derived fair value of CNY 25.05 provides a >40% upside potential. With a cash pile of CNY 2.71 bn against modest debt of CNY 0.14 bn, a dividend yield of 2.97% and a payout ratio near 61%, the dividend appears sustainable. The low beta (~0.24) and strong cash generation offset the relatively high volatility (≈24% 30‑day) and moderate leverage, positioning the stock as an undervalued, dividend‑supportive play in the specialty pharma CDMO space.